A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
NCT ID: NCT00705770
Last Updated: 2012-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2/PHASE3
INTERVENTIONAL
2008-05-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
NCT00570479
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
NCT00047606
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
NCT03488550
IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients
NCT00533962
Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.
NCT05606796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo treatment with vehicle
Placebo
Placebo treatment with vehicle
2
Low dose of study medication
Anecortave Acetate
Low dose
Sustained release depot suspension
3
Middle dose of study medication
Anecortave Acetate
Middle dose
Sustained release depot suspension
4
High dose of study medication
Anecortave Acetate
High dose
Sustained release depot suspension
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anecortave Acetate
Low dose
Sustained release depot suspension
Anecortave Acetate
Middle dose
Sustained release depot suspension
Anecortave Acetate
High dose
Sustained release depot suspension
Placebo
Placebo treatment with vehicle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-07-58
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.